share_log

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Plus Therapeutics 宣布首位患者在治疗复发性胶质母细胞瘤的硒 (186Re) Obisbemeda 的 respect-GBM 2b 期试验中给药
Benzinga Real-time News ·  2023/01/18 07:02

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Plus Therapeutics 宣布首位患者在治疗复发性胶质母细胞瘤的硒 (186Re) Obisbemeda 的 respect-GBM 2b 期试验中给药

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发